The role of splenectomy in children with juvenile myelomonocytic leukemia

Area of Science:

• Pediatric Hematology
• Oncology
• Surgical Oncology

Background:

• Splenectomy is a palliative treatment for myelodysplastic syndrome (MDS).
• Limited data exists on post-splenectomy outcomes in pediatric MDS.
• Juvenile myelomonocytic leukemia (JMML) is a rare pediatric MDS subtype.

Purpose of the Study:

• To evaluate the impact of splenectomy on the outcomes of children with JMML.
• To assess the safety and efficacy of splenectomy in refractory JMML cases without HLA-identical donors.
• To determine changes in hematological parameters and quality of life post-splenectomy.

Main Methods:

• Retrospective analysis of six children with JMML undergoing splenectomy.
• Indications for splenectomy included persistent thrombocytopenia, high erythrocyte transfusion requirements, and massive splenomegaly.
• Outcomes assessed included hemoglobin levels, platelet counts, transfusion needs, and quality of life.

Main Results:

• Five of six patients showed improved hemoglobin values and platelet counts post-splenectomy.
• Erythrocyte transfusion requirements decreased significantly, with responders remaining transfusion-independent for at least six months.
• Quality of life improved markedly in responding patients.
• No splenectomy-related mortality was observed.

Conclusions:

• Splenectomy is a safe and effective supportive treatment for select children with JMML.
• It can improve hematological parameters and reduce transfusion dependency.
• Splenectomy offers a viable option for JMML patients unresponsive to chemotherapy and lacking HLA-identical donors.